Tevogen Bio Holdings Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $11.1M | $31.0M | $4.4M | — | — |
| Operating expenses | $26.1M | $53.6M | $8.8M | — | — |
| Operating income | -$26.1M | -$53.6M | -$8.8M | — | — |
| Interest expense | — | $184,037 | $1.2M | — | — |
| Income tax expense | $4,750 | $1,750 | — | — | — |
| Net income | -$26.3M | -$13.7M | -$60.5M | $4.4M | — |
| Balance Sheet | |||||
| Cash and equivalents | $0 | $0 | $0 | $129,186 | $344,581 |
| Current assets | $1.5M | $2.4M | $1.7M | $274,356 | $791,191 |
| Total assets | $4.4M | $3.5M | $5.5M | $357.1M | $352.9M |
| Current liabilities | $7.1M | $9.0M | $85.5M | $350,454 | $59,375 |
| Total liabilities | $12.6M | $10.1M | $99.9M | $15.1M | $15.2M |
| Stockholders' equity | -$8.2M | -$6.7M | -$94.4M | -$34.0M | -$14.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.3M | -$12.0M | -$8.2M | -$215,395 | — |
| Depreciation and amortization | $190,573 | $162,209 | $163,300 | — | — |
| Stock-based compensation | $16.2M | $40.8M | — | — | — |
| Capital expenditure | $64,439 | — | $133,000 | — | — |
| Free cash flow | -$12.4M | — | -$8.3M | — | — |
| Share repurchases | — | — | $343.0M | — | — |
Shares outstanding 4.2M
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.